The UK and Japan have reached an agreement on the terms of a future trade deal. This will allow pharmaceutical companies in the UK to continue trading largely as they do now come 1 January 2021.
The MHRA has published information for pharmaceutical companies preparing for the end of the Brexit transition period.
The Health Secretary has announced that Public Health England is to be replaced with a new body called the National Institute for Health Protection, in a merger of the pandemic response work of PHE and NHS Test and Trace.
The DHSC has published a letter setting out the government’s plan and requests of industry and the wider supply chain ahead of the end of the Brexit transition period to help ensure the continuity of supply of medical goods into and out of the UK.
In his speech, the Chancellor Rishi Sunak outlined important short-term measures to support businesses hit by the coronavirus pandemic.
More than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030.
The Independent Medicines and Medical Devices Safety Review, chaired by Baroness Julia Cumberlege, has published its report.
The Government should take immediate action to ‘supercharge’ private and public sector investment if it is to keep UK industries globally competitive, a new report by the Office for Health Economics warns.
The Government has published its R&D Roadmap with plans to cement the UK as the world’s leading research and science superpower.
The data published on Disclosure UK today shows that the industry invested £381.2 million on R&D activities in the UK during 2019, up from £377.3million in 2018.